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resolvin D1 on spinal nociceptive
processing in rat pain models
Pongsatorn Meesawatsom1, James Burston1, Gareth Hathway1, Andrew Bennett2 and Victoria Chapman1*Abstract
Background: Harnessing the actions of the resolvin pathways has the potential for the treatment of a wide range
of conditions associated with overt inflammatory signalling. Aspirin-triggered resolvin D1 (AT-RvD1) has robust
analgesic effects in behavioural models of pain; however, the potential underlying spinal neurophysiological
mechanisms contributing to these inhibitory effects in vivo are yet to be determined. This study investigated the
acute effects of spinal AT-RvD1 on evoked responses of spinal neurones in vivo in a model of acute inflammatory
pain and chronic osteoarthritic (OA) pain and the relevance of alterations in spinal gene expression to these
neurophysiological effects.
Methods: Pain behaviour was assessed in rats with established carrageenan-induced inflammatory or monosodium
iodoacetate (MIA)-induced OA pain, and changes in spinal gene expression of resolvin receptors and relevant
enzymatic pathways were examined. At timepoints of established pain behaviour, responses of deep dorsal horn
wide dynamic range (WDR) neurones to transcutaneous electrical stimulation of the hind paw were recorded pre- and
post direct spinal administration of AT-RvD1 (15 and 150 ng/50 μl).
Results: AT-RvD1 (15 ng/50 μl) significantly inhibited WDR neurone responses to electrical stimuli at C- (29 %
inhibition) and Aδ-fibre (27 % inhibition) intensities. Both wind-up (53 %) and post-discharge (46 %) responses of WDR
neurones in carrageenan-treated animals were significantly inhibited by AT-RvD1, compared to pre-drug response (p <
0.05). These effects were abolished by spinal pre-administration of a formyl peptide receptor 2 (FPR2/ALX)
antagonist, butoxy carbonyl-Phe-Leu-Phe-Leu-Phe (BOC-2) (50 μg/50 μl). AT-RvD1 did not alter evoked WDR
neurone responses in non-inflamed or MIA-treated rats. Electrophysiological effects in carrageenan-inflamed rats
were accompanied by a significant increase in messenger RNA (mRNA) for chemerin (ChemR23) receptor and 5-
lipoxygenase-activating protein (FLAP) and a decrease in 15-lipoxygenase (15-LOX) mRNA in the ipsilateral spinal
cord of the carrageenan group, compared to controls.
Conclusions: Our data suggest that peripheral inflammation-mediated changes in spinal FLAP expression may
contribute to the novel inhibitory effects of spinal AT-RvD1 on WDR neuronal excitability, which are mediated by
FPR2/ALX receptors. Inflammatory-driven changes in this pathway may offer novel targets for inflammatory pain
treatment.
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Abbreviations: 15-LOX, 15-Lipoxygenase; 15-PGDH, 15-Hydroxyprostaglandin dehydrogenase; 17R-RvD1, 17R-
Resolvin D1; 17S-H(p)-DHA, 17S-Hydroperoxy docosahexaenoic acid; 17S-RvD1, 17S-Resolvin D1; 3×, Three times;
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5-LOX, 5-Lipoxygenase; ANOVA, Analysis of variance; AP, Action potential; AT-RvD1, Aspirin-triggered resolvin D1;
BOC-2, Butoxy carbonyl-Phe-Leu-Phe-Leu-Phe; cDNA, Complementary deoxyribonucleic acid; ChemR23, Chemerin
receptor; COX-2, Cyclooxygenase-2; DHA, Docosahexaenoic acid; FLAP, 5-Lipoxygenase-activating protein; FPR2/
ALX, Formyl peptide receptor 2; g, Gram; GFAP, Glial fibrillary acidic protein; GPR32, G-protein-coupled receptor
32; h, Hour; Hz, Hertz; IL-10, Interleukin-10; l, Litre; M, Molar; MIA, Monosodium iodoacetate; min, Minute;
μl, Microlitre; μm, Micrometre; mm, Millimetre; ms, Millisecond; NeuN, Neuronal nuclear antigen; ng, Nanogram;
NMDA, N-Methyl-D-aspartate; OA, Osteoarthritis; °C, Degree Celsius; PBS, Phosphate-buffered saline; PD, Post-
discharge; PWT, Paw withdrawal threshold; RNA, Ribonucleic acid; RvD1, Resolvin D1; RvE1, Resolvin E1;
SEM, Standard error of mean; SPMs, Specialised proresolving mediators; TNF-α, Tumour necrosis factor-α;
WDR, Wide dynamic range; wt, Weight; WU, Wind-upBackground
Untreated pain remains a major clinical problem, and
there is a need for the identification of novel therapeutic
approaches for both acute and chronic pain states.
Sustained activation of the pain pathways is underpinned
by the actions of peripheral and spinal inflammatory
cells, peripheral sensitization of nerve terminals and the
plasticity of the spinal neuronal circuits activated [1, 2].
It is established that nociceptive afferent barrage leads to
changes within the spinal cord, including the relatively
quick up- and down-regulation of genes for various
enzymatic pathways [3–5], which may act to promote
nociceptive responses and drive hyperalgesia or act to
counteract these events.
Specialised proresolving mediators (SPMs) such as the
essential fatty acid-derived lipoxins, resolvins, protectins
and maresins [6, 7] have robust inhibitory effects on
inflammatory signalling pathways. This has been particu-
larly well evidenced for the D-series resolvins, specific-
ally resolvin D1 (RvD1 or 17S-RvD1) and its isomer,
aspirin-triggered RvD1 (AT-RvD1 or 17R-RvD1), which
are SPMs derived from the polyunsaturated fatty acid
docosahexaenoic acid (DHA) [8]. SPMs are generated
after an overt inflammatory insult to promote resolution
[6], and this is achieved by the inhibition of pro-
inflammatory cytokine production and shortening of the
interval between inflammation and resolution by inhibit-
ing neutrophil infiltration and stimulating macrophage
phagocytosis [6]. Endogenous synthesis of the D-series
resolvins is via the 15-lipoxygenase (15-LOX)-mediated
conversion of DHA to hydroperoxy intermediates (see
Additional file 1: Figure S1). Synthesis of AT-RvD1 is en-
hanced by aspirin [8] via the acetylation of a serine resi-
due on cyclooxygenase-2 (COX-2), to permit enzymatic
conversion of DHA to a 17R-hydroperoxy intermediate,
prior to 5-lipoxygenase (5-LOX)-mediated RvD1/AT-
RvD1 formation. RvD1 and AT-RvD1 are rapidly meta-
bolised, predominantly by 15-prostaglandin dehydrogen-
ase to 8-oxo and 17-oxo metabolites [9]. A metabolically
more stable analogue of resolvin D1 has been developed
with similar potency in reducing neutrophil infiltrationand increasing macrophage phagocytosis [10]. The bio-
logical effects of RvD1 and AT-RvD1 have been attrib-
uted to the G-protein-coupled receptor GPR32 and
formyl peptide receptor 2 (FPR2/ALX), utilising Gi and
possibly Gq as signal transductions [11, 12]. Both recep-
tors are expressed in human tissue, but GPR32 is not yet
identified in rodents [13].
Despite their rapid degradation, locally administered
RvD1 and AT-RvD1 have analgesic effects in various animal
models of pain [13–17]. In carrageenan-induced inflamma-
tory pain, intraplantar administration of RvD1 attenuated
paw oedema and heat hyperalgesia [14]. Single intrathecal
administration of RvD1 or AT-RvD1 rapidly decreased heat
pain thresholds and reduced mechanical hypersensitivity in
behavioural tests in the carrageenan model [13, 14]. The
spinal neuronal mechanisms underlying these neurophysio-
logical effects on pain behaviour have yet to be elucidated.
The future exploitation of this potential novel class of
analgesics requires a comprehensive understanding of
their sites and mechanisms of action and the conditions
under which inhibitory effects are evident. Here, we char-
acterise the neurophysiological mechanism effects under-
pinning the effects of AT-RvD1 on spinal nociceptive
processing using in vivo electrophysiology in two models
of pain. Acute effects of spinal administration of AT-RvD1
on evoked spinal neuronal responses were characterised
in the carrageenan-induced model of inflammatory pain
and monosodium iodoacetate (MIA) model of chronic
joint pain. To advance mechanistic understanding of this
system in the spinal cord, gene expression of the known
resolvin receptors in the rodent (FPR2/ALX and chemerin
(ChemR23) receptor) and relevant enzymatic pathways, in
particular 15-LOX and 5-LOX, were quantified in the
model of inflammatory pain, compared to the relevant
control group.
Methods
Animals
Male Sprague Dawley rats (n = 84) were purchased from
Charles River, UK. The initial weight ranges were 200–
250 g and 175–220 g on the day of carrageenan and
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accordance with the UK Home Office Animals (Scientific
Procedures) Act (1986) and followed the guidelines of the
International Association for the Study of Pain [18] and
were approved by the local ethical review board at the
University of Nottingham. Rats were group housed at the
Bio Support Unit, University of Nottingham, in open cages
and fed ad libitum. In accordance with the ARRIVE
guidelines [19], full details of the group sizes for the
different studies and experimental endpoints are in
Additional file 1: Table S1.
Induction of pain models
Under brief anaesthesia (isoflurane 2.5–3 % in O2
1 l/min), rats were injected with either intraplantar
2 % λ-carrageenan 100 μl (Sigma, UK) or vehicle (0.9 %
saline) into the glabrous surface of the left hind paw [20]
or intra-articular 1 mg/50 μl of MIA (Sigma, UK) or
vehicle injection via infra-patella ligament [21].
Pain behaviour measurements
Pain behaviour was quantified as previously described
[21, 22] in a blinded fashion at baseline, 2 and 8 h post
carrageenan injection and twice a week post MIA injec-
tion for 28 days. Weight bearing asymmetry, reflecting the
change in weight bearing from the ipsilateral hind limb to
the contralateral hind limb, was measured using an inca-
pacitance tester (Linton Instrumentation, UK). Paw with-
drawal thresholds (PWTs) of both hind paws were
assessed using the up-down method [23] with von Frey
monofilaments with a range of bending forces (1, 1.4, 2, 4,
6, 8, 10, 15 and 26 g), starting for 4 g. Once a withdrawal
reflex was observed, the next descending monofilament
was applied to retest until no response was elicited. PWT
was determined as the lowest force of monofilament
which evoked a paw withdrawal reflex [24].
In vivo spinal electrophysiology
Single-unit in vivo electrophysiology recording of deep
dorsal horn wide dynamic range (WDR) neurones was
performed, as previously described [25] on the day follow-
ing carrageenan injection or on days 28–32 post MIA
injection.
Rats were anaesthetised with isoflurane (3 % induction,
2 % surgery, 1.5–1.75 % maintenance) in 0.6 l/min N2O
and 0.3 l/min O2, and a tracheal cannula was inserted.
Rats were placed in a stereotaxic frame, and a laminec-
tomy was performed to expose the L4–L5 region of the
spinal cord receiving the input from the hind paw. The
size of the laminectomy was kept to a minimum; only
the narrow centre strip of tissue and vertebrae was re-
moved, leaving the edges of the vertebrae covered by the
surrounding paraspinal muscles to form a natural well-
retaining applied fluid. The spinal column was held rigidby clamps caudal and rostral to the exposed section.
Core body temperature was maintained (36.5–37 °C) via
a homeothermic heated blanket linked to a rectal probe
(Harvard Instruments, UK). A glass-coated tungsten mi-
croelectrode was slowly lowered into the ipsilateral side
of the dorsal horn using a SCAT-01 Microdrive (Digitimer,
UK) in 10-μm steps. Electrical activity was amplified, fil-
tered by a Neurolog system (Digitimer, UK), digitised by
CED Micro1401 (Cambridge Electronic Design, Cambridge,
UK) and captured/analysed by Spike 2 version 6.05 software
(Cambridge Electronic Design, UK). Single neurones lo-
cated between 500 and 1000 μm from the surface of the
spinal cord were recorded. Neurones that responded to
both innocuous mechanical stimuli (gently tapping)
and noxious stimuli (pinching) were defined as being
WDR. Responses of WDR neurones following a train of
16 (0.5 Hz, 2-ms pulse width) consecutive transcutane-
ous electrical stimuli delivered at the centre of the area
on the hind paw eliciting the WDR neurone responses
were characterised. The advantages of transcutaneous
electrical stimulation include controlled and reprodu-
cible stimulus delivery in the presence of tissue inflam-
mation [26], quantification of distinct peripheral fibre
group-evoked responses and the bypassing of periph-
eral transduction process to ensure that any changes in
neuronal responses are centrally mediated [27]. All se-
lected neurones had a clear short-latency Aβ-fibre-
evoked response followed by a C-fibre-evoked response.
A single electrical stimulus was applied at increasing
amplitude in 0.1-mA steps; when a single action poten-
tial was elicited in a 90–300-ms post-stimulus range,
the stimulus amplitude was taken as the C-fibre thresh-
old and the latency were recorded. Aβ-fibre threshold
and latency were measured in the same manner but
with a 0.01-mA amplitude increment and in a 0–20-ms
post-stimulus range. Responses were elicited at three
times (3×) the threshold for C-fibres and then 3× the
threshold for Aβ fibres, and post-stimulus histograms
were built. Note that C-fibre stimulus intensity also
activates Aβ and Aδ fibres which will modulate WDR
neurone responses. The Aβ-fibre-evoked responses
were taken as the action potential number recorded 0–
20 ms after the electrical stimulus, Aδ-fibre-evoked re-
sponses were taken as the action potential number re-
corded 20–90 ms after the electrical stimulus, and C-fibre-
evoked responses were taken as the action potential num-
ber recorded 90–300 ms after the electrical stimulus. The
remaining neuronal response (300–800 ms post stimulus)
was defined as the post-discharge (PD) of the neurone. The
input (non-potentiated response) was calculated as the num-
ber of action potentials in C-fibre and PD bands produced by
the first stimulation (initial baseline response) multiplied by
the total number of stimuli (16). Wind-up (WU, potentiated
response) [28] was calculated as the difference between the
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produced by the train of 16 stimuli minus the input. Cycles of
the electrical stimulations were carried out in 15-min
intervals.
Pharmacological studies
Following stable control-evoked neuronal responses
(<10 % variation of C-fibre responses), drugs were applied
topically to the surface of the exposed L4-5 segments of
the spinal cord via a Hamilton syringe in 50-μl volume.
Concentrations of AT-RvD1 and butoxy carbonyl-Phe-
Leu-Phe-Leu-Phe (BOC-2), a FPR2/ALX receptor antag-
onist [29], were based on previous studies [13, 30]. AT-
RvD1 and RvD1 have similar chemical structures; how-
ever, AT-RvD1 is more resistant to enzymatic inactivation
by 15-hydroxyprostaglandin dehydrogenase (15-PGDH)
[9]. In the carrageenan study, saline- or carrageenan-pre-
treated rats received one of the following spinal treat-
ments: AT-RvD1 (Cayman Chemical, USA) 15 ng in 50 μl
PBS (phosphate-buffered saline); vehicle (50 μl PBS);
BOC-2 (Phoenix Pharmaceuticals, Inc., USA) 50 μg in
50 μl 3 % Tween 80 + 0.5 % ethanol in saline; BOC-2
50 μg in 50 μl 3 % Tween 80 + 0.5 % ethanol in saline for
15 min and then AT-RvD1 at 15 ng. In the MIA study,
saline- and MIA-treated rats received spinal AT-RvD1 cu-
mulatively (15 ng and 150 ng /50 μl) and then spinal
morphine sulphate (Queen’s Medical Centre Pharmacy,
Nottingham, UK) 1 μg/50 μl in PBS vehicle. Previous drug
solution was removed from the spinal cord between treat-
ments. Effects of treatments on electrically evoked
responses of neurones were followed for 60 min post
treatment. Full details of the group sizes are provided in
Additional file 1: Table S1.
Gene expression study
In separate cohorts of intraplantar saline- (n = 6) and
carrageenan-injected rats (n = 5), pain behaviour was
assessed as previously described. Rats were sacrificed by
cranial concussion and decapitated (Schedule 1 of the
Animal (Scientific Procedure) Act 1996) at 30 h post carra-
geenan induction. The lumbar enlargement (L4–L6) of the
spinal cord was dissected free and the ipsilateral dorsal
horn quadrant was frozen on dry ice and stored at −80 °C
until use. Note that the collected samples are a mixture of
all cell types, e.g. neurones, microglia and astrocytes. After
treating with 2 ml ice-cold Tri reagent (Sigma Aldridge,
UK), total RNA was extracted and purified from the tissue
samples according to the manufacturer’s instructions. Com-
plementary DNA (cDNA) was synthesised by reverse tran-
scription from 500 ng total RNA using SuperScript III
(Invitrogen, UK) reverse transcriptase according to themanu-
facturer’s instructions. Reactions were incubated at 25 °C for
10 min, 37 °C for 50 min and followed by 70 °C for 15 min to
terminate the reaction. Gene expression quantification wasperformed as previously described [31, 32]. Genes examined
relative to β-actin were FPR2/ALX, ChemR23, 5-LOX, 15-
LOX, COX-2, 5-lipoxygenase-activating protein (FLAP) and
interleukin-10 (IL-10). Primers and probes were based on a
previous study [5] or designed by Primer Express 3.0 software
and synthesised by MWG Biotech (Germany); sequences are
in Additional file 1: Table S2.
Macroscopic assessments
The circumference of ipsilateral paw was measured at
baseline and 24 h post carrageenan injection as previ-
ously described [20, 33]. Ipsilateral knee joints of rats in
the MIA study were collected at the end of the study
and were disarticulated. Macroscopic scoring of knee
joint pathology was based on a previously reported scoring
system [34]. The severity of the pathology of the cartilage
surface was graded as follows: 0 = normal appearance,
1 = slight yellowish discoloration of the chondral sur-
face, 2 = little cartilage erosions in load-bearing areas,
3 = large erosions extending down to the subchondral
bone, and 4 = large erosions with large areas of subchon-
dral bone exposure. Six compartments were scored in-
cluding medial femoral condyle, lateral femoral condyle,
medial tibial plateau, lateral tibial plateau, femoral groove
and patella and then were combined to give a total score
(possible maximum score 24). Abnormal growth of bone
was recorded as osteophyte presentation. The experi-
menter was blinded for the induction procedure.
Statistical analysis
GraphPad Prism 6.05 (GPP 6.05; GraphPad Software,
Inc, San Diego, CA) was used for statistical analyses and
graphical presentation. Data were excluded from the stat-
istical analysis where outliers were identified by Grubb’s
test at α = 0.05. Results are expressed as mean ± standard
error of mean (SEM). Kolmogorov-Smirnov test was used
to determine whether data are normally distributed. Per-
centage of weight (wt) bearing asymmetry was calculated
from the formula [(Contralateral wt − Ipsilateral wt) /
(Contralateral wt + Ipsilateral wt)] × 100. Pain behaviour
data were analysed with a two-way analysis of variance
(ANOVA) with Sidak post hoc test. Differences in paw cir-
cumference between carrageenan and saline and chondro-
pathy scores between MIA versus saline were analysed
using a Mann-Whitney U test. Raw data from the electro-
physiological study using the carrageenan model were
analysed with paired t tests or Wilcoxon tests. In the MIA
study, raw data from the electrophysiological study were
compared to baseline using repeated measure ANOVA
followed by Sidak post hoc test or Friedman statistics
followed by Dunn’s post hoc test. Percentages of maximal
inhibition were calculated versus baseline (pre-drug
responses) and were compared between groups using
Kruskal-Wallis test with Dunn’s post hoc test. Statistical
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Mann-Whitney U test. Statistical significance is considered
where p value is ≤0.05 for all comparisons.
Results
Carrageenan-mediated hind paw inflammation resulted in
alterations in WDR neurone responses
Initial paw circumferences of saline- and carrageenan-
treated rats were comparable, 25 ± 0.3 and 26 ± 0.2 mm,
respectively. Carrageenan-treated rats exhibited robusta
b
Fig. 1 Carrageenan-evoked pain behaviour and paw inflammation.
Intraplantar injection of 2 % λ-carrageenan significantly increased
weight bearing asymmetry (a) and decreased mechanical PWT (b)
from 2 to 8 h post injection. ****p < 0.0001 versus the saline-treated
group, two-way repeated measure ANOVA with Sidak post hoc test.
Saline n = 15 and carrageenan n = 38weight bearing asymmetry and lowered PWTs at 2 and
8 h post injection, compared to saline-treated rats
(Fig. 1a, b). Intraplantar injection of carrageenan also
produced a profound paw swelling, evident at 1–2 h and
significant at 24 h post injection compared to saline-
treated rats (carrageenan 33 ± 0.28 mm; saline 25.8 ±
0.29 mm, p < 0.0001).
WDR neurones (n = 53) were characterised in a total
of 53 rats (saline-treated n = 15 and carrageenan-treated
n = 38) at 24 h after intraplantar injection of saline or
carrageenan (Table 1). The mean depths of neurones of
all groups were within the 500–1000-μm range, corre-
sponding to laminae V–VI (Table 1). Comparison of
thresholds of evoked responses of WDR neurones
revealed higher thresholds for Aβ- and C-fibre-evoked
responses in the carrageenan-treated group (Table 1).
Aβ- and C-fibre latencies and magnitudes of evoked firing
of WDR neurones were not altered in the carrageenan-
treated group, compared to the saline controls. Aδ-fibre-
evoked responses of WDR neurones were significantly
facilitated in carrageenan-treated rats (163 %) compared
to saline-treated rats. There was a trend towards an in-
crease in the input response in carrageenan-treated rats,
but significance was not reached. There were no differ-
ences in the magnitudes of the other evoked responses of
the WDR neurones in the carrageenan-treated group
compared to saline controls.Table 1 Comparison of characteristics of WDR neurones in
carrageenan versus saline-treated rats
Saline-treated
(n = 15)
Carrageenan-treated
(n = 38)
% Change vs
saline-treated
Depth (μm) 677 ± 31 747 ± 21 NA
Threshold (mA)
Aβ 0.14 ± 0.01 0.19 ± 0.01## 130
C 1.47 ± 0.08 1.81 ± 0.10* 124
Latency (ms)
Aβ 7.6 ± 0.79 7.3 ± 0.40 96
C 182.3 ± 8.76 191.0 ± 8.50 105
Electrically evoked responses (number of APs)
Aβa 121 ± 10 126 ± 8 104
Aβb 143 ± 10 145 ± 8 101
Aδb 91 ± 16 148 ± 17## 163
Cb 431 ± 49 497 ± 41 114
PDb 352 ± 49 381 ± 37 106
Inputb 271 ± 51 368 ± 60 136
WUb 505 ± 60 502 ± 46 100
Characteristics of spinal WDR neurones recorded at approximately 30 h
following intraplantar injection of 2 % λ-carrageenan or saline
*p < 0.05 unpaired t test, ##p < 0.01 Mann-Whitney U test
APs action potentials, NA not applicable
aResponses electrically evoked by 3× Aβ-fibre threshold
bResponses electrically evoked by 3× C-fibre threshold
Aβa b
c d
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Fig. 2 (See legend on next page.)
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Fig. 2 Effect of spinal administration of AT-RvD1 on evoked responses of WDR neurons. Spinal administration of AT-RvD1 selectively inhibited
nociceptive fibre-evoked responses of spinal WDR neurones in carrageenan-treated rats, which were mediated mainly by FPR2/ALX receptor activation. In
saline-treated rats (white bars), electrically evoked responses were not altered by PBS (n= 5) vehicle or AT-RvD1 (n= 10), except the input response which
was slightly facilitated by AT-RvD1 (e third and fourth bars). AT-RvD1 (15 ng/50 μl) resulted in a non-significant decrease in Aβ-fibre-evoked responses
(p= 0.0781) in carrageenan-treated rats (grey bars, n= 9). Spinal AT-RvD1 significantly suppressed WDR neurone responses evoked by electrical stimulation
of Aδ and C fibres (b, c) as well as PD, input and WU (d–f) responses when compared to pre-drug responses. g Illustrates the effect of AT-RvD1 on WU of
WDR neurones following 16 electrical stimulations in carrageenan-treated rats. At 15 min post AT-RvD1, the AUC was significantly lowered when compared
to baseline (g inset). h Is an example of the electrically evoked responses of a WDR neurone recorded for 60 min following AT-RvD1
application in a carrageenan-treated rat. Data in a–f are mean maximal number of action potentials post drug application. *p < 0.05, **p < 0.01 paired t
test. ##p < 0.001 Wilcoxon test, n = 8–10 group, except for saline-PBS n = 5. APs action potentials
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the carrageenan model of hind paw inflammation
The mean time of spinal administration of AT-RvD1 was
29.2 ± 0.2 h (range 26.3–32.2 h) post carrageenan injection.
Effects of AT-RvD1 versus PBS on evoked responses of
spinal neurones were determined for 60 min after applica-
tion to the surface of the spinal cord. Spinal administration
of PBS did not alter any parameters in either saline- or
carrageenan-treated rats. In the carrageenan-treated group,
responses of 9 out of 10 neurones were inhibited by spinal
administration of AT-RvD1. Maximal inhibition of evoked
responses was observed between 25 and 39 min post
treatment. Spinal administration of AT-RvD1 (15 ng)
did not significantly alter Aβ-fibre-evoked responses
in carrageenan-treated rats (Fig. 2a). This treatment
did however significantly attenuate Aδ- and C-fibre-
evoked responses WU and PD of WDR neurones in
carrageenan-treated rats but not saline-treated rats
(Fig. 2b–d, f and Table 2). There was a significant increase
in input responses following treatment with spinal admin-
istration of AT-RvD1 in saline-treated rats (Fig. 2e). AUCTable 2 Mean maximal percentage inhibition of evoked responses
by AT-RvD1
Group effect (% maximal inhibition)
Saline-treated Carrageenan-treated
AT-RvD1 (n = 10) AT-RvD1 (n = 9) AT-RvD1 post BOC-2 (n = 8)a
Aβ 2 ± 9 11 ± 13 5 ± 9
Aδ −14 ± 12 27 ± 7* −13 ± 8#
C −10 ± 10 29 ± 5** −1 ± 6#
PD −19 ± 23 46 ± 8 −9 ± 14#
Input −19 ± 15 41 ± 8* −9 ± 14
WU −10 ± 15 53 ± 12** −1 ± 7#
Comparison of group effects of AT-RvD1 (15 ng/50 μl) on electrically evoked
responses of spinal WDR neurones in carrageenan-treated rats versus
saline-treated rats and the effects of pre-treatment with BOC-2 50 μg/
50 μl (expressed as % maximal inhibition). AT-RvD1 significantly inhibited
a number of evoked parameters in carrageenan-treated-rats but not saline-
treated rats. Pre-treatment with BOC-2 significantly prevented the inhibitory
effects of AT-RvD1 for most of the parameters. Note that negative values
indicate facilitation
*p < 0.05, **p < 0.01 compared to AT-RvD1 in the saline-treated group, #p < 0.05
compared to AT-RvD1 in the carrageenan-treated group without BOC-2,
Kruskal-Wallis test with Dunn’s post hoc test
aOne neurone was inhibited by BOC-2 and was excluded from further analysisof the stimulus-response curve representing WU follow-
ing AT-RvD1 versus PBS was significantly different
(Fig. 2g, p < 0.05). An example of evoked responses of a
WDR neurone following AT-RvD1 administration in a
carrageenan-treated rat is shown in Fig. 2h.
To investigate the potential role of the FPR2/ALX re-
ceptor in the effects of AT-RvD1 on evoked responses of
spinal neurones, the effects of spinal administration of
BOC-2 (50 μg/50 μl) was tested in carrageenan-treated
rats (n = 9 rats). Spinal administration of BOC-2 alone
did not alter the evoked firing of spinal neurones com-
pared to pre-drug (Additional file 1: Figure S2). A 15-
min spinal pre-treatment with BOC-2 inhibited the
effects of AT-RvD1 on evoked neuronal responses in
carrageenan-treated rats (n = 8; Table 2). There were
significant differences in the mean maximal percentage
inhibition of evoked responses of WDR neurones by AT-
RvD1 in the presence versus absence of BOC-2 in
carrageenan-treated rats (Table 2).
AT-RvD1 had minimal effect on WDR neurone responses
in the MIA model of joint pain
Intra-articular injection of MIA resulted in significant
weight bearing asymmetry, lowered hind paw withdrawal
thresholds and joint pathology consistent with previous
studies (Table 3). The baseline characteristics of spinal
WDR neurones in MIA-treated rats were comparable to
saline-treated rats (Table 3). At 28–32 days following
model induction, rats were prepared for spinal record-
ings. Neurone depths, thresholds and latencies of Aβ
and C-fibre of neurons in MIA-treated rats (n = 9) were
comparable to those in saline-treated rats (n = 7).
In general, spinal administration of AT-RvD1 (15 and
150 ng) did not alter evoked responses of spinal neurones
in either MIA- or saline-treated rats (Fig. 3a–f). To ascer-
tain whether there was a shift in efficacy of treatment, a
higher dose of AT-RvD1 (150 ng) was also studied. This
dose produced a small but significant inhibition of Aδ-
fibre-evoked responses of WDR neurones in MIA-treated
rats, compared to baseline (Fig. 3b), but did not alter other
responses. Spinal administration of morphine (1 μg/50 μl)
significantly attenuated Aδ- and C-fibre-evoked responses
of spinal neurones in both MIA- and saline-treated rats
Table 3 Comparison of pain behaviour, joint pathology and characteristics of WDR neurones in the MIA model of OA pain
Saline-treated (n = 9) MIA-treated (n = 11) % change vs saline-treated
Pain behaviour day 28
% weight bearing difference 2 ± 2 15 ± 2** NA
PWT (g) 17 ± 2.7 6 ± 0.8** NA
Knee joint pathology
Macroscopic score 0 ± 0.14 14 ± 1.5**** NA
Presence of osteophytes 0/9 10/11 NA
Number of analysed neurones 7 9
Depth (μm) 780 ± 48 720 ± 47
Threshold (mA)
Aβ 0.14 ± 0.01 0.14 ± 0.01 100
C 1.41 ± 0.12 1.54 ± 0.14 109
Latency (ms)
Aβ 7.4 ± 1.04 7.5 ± 0.73 101
C 187.6 ± 24 141.1 ± 15 75
Electrically evoked responses (number of APs)
Aβa 129 ± 14 121 ± 14 94
Aβb 151 ± 12 135 ± 12 89
Aδb 146 ± 16 118 ± 19 81
Cb 384 ± 52 419 ± 49 109
PDb 394 ± 42 365 ± 67 93
Inputb 280 ± 52 362 ± 61 129
WUb 502 ± 63 426 ± 56 85
Pain behaviour (weight bearing difference and hind paw withdrawal thresholds) was assessed at 28 days following intra-articular injection of MIA. Spinal WDR neurones
were recorded at 28–32 days following intra-articular injection of MIA or saline. Knee joint pathology was assessed following electrophysiological recordings
APs action potentials, NA not applicable for behavioural data
**p < 0.01, ****p < 0.0001 Mann-Whitney U test
aResponses electrically evoked by 3× Aβ-fibre threshold
bResponses electrically evoked by 3× C-fibre threshold
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inhibition of Aβ-fibre-evoked responses of WDR neurones
in saline-treated rats (Fig. 3a). Comparison of the maximal
effect of morphine on evoked responses of WDR neurones
revealed no significant differences between MIA- and
saline-treated rats (Table 4).
The impact of peripheral inflammation on the spinal
expression of the resolvin receptors and related
enzymatic pathways
In separate groups of rats, ipsilateral dorsal horns of the
spinal cord were collected at 30 h following intraplantar
injection of carrageenan. β-actin messenger RNA (mRNA)
expression was comparable in both groups of rats (saline
0.3068 ± 0.013 versus carrageenan 0.2965 ± 0.016) serving
as a suitable reference gene for relative comparisons. Fol-
lowing intraplantar injection of carrageenan, levels of
FPR2/ALX mRNA remained stable in the dorsal horn of
the spinal cord, compared to saline-treated rats (Fig. 4a).
Carrageenan treatment was associated with a significantincrease (1.5-fold, p < 0.05) in ChemR23 mRNA expression
(Fig. 4b). Focusing on enzymes involved in resolvin biosyn-
thesis, 5-LOX mRNA expression in the dorsal horn of the
spinal cord was similar in carrageenan- and saline-treated
rats (Fig. 4c). However, expression of the 5-LOX-activating
protein FLAP was significantly higher (1.3-fold in-
crease, p < 0.05) in the dorsal horn of the spinal cord of
carrageenan-treated rats, compared to saline controls
(Fig. 4e). Expression of 15-LOX mRNA level was signifi-
cantly lower in carrageenan-treated rats when compare to
saline-treated rats (p < 0.05, Fig. 4d).
Discussion
Previous studies reported acute inhibitory effects of spinal
resolvins on behavioural responses to painful stimuli. The re-
sults reported herein demonstrate that spinal administration
of AT-RvD1 did not alter physiological spinal nociceptive
responses but significantly attenuated evoked nociceptive
responses of dorsal horn spinal neurones following a 24-h
period of peripheral inflammation of the hind paw. At the
Aβa b
c d
e fPD
Aδ
InputC-fibre
Pre 15 ng 150 ng 1 ug Pre 15 ng 150 ng 1 ug
Pre 15 ng 150 ng 1 ug Pre 15 ng 150 ng 1 ug
Pre 15 ng 150 ng 1 ug Pre 15 ng 150 ng 1 ug
Pre 15 ng 150 ng 1 ug Pre 15 ng 150 ng 1 ug
Pre 15 ng 150 ng 1 ug Pre 15 ng 150 ng 1 ug
Pre 15 ng 150 ng 1 ug Pre 15 ng 150 ng 1 ug
WU
Fig. 3 Minimal effects of AT-RvD1 on spinal WDR neurones in MIA-treated rats. On day 28 post model induction (intra-articular 1 mg MIA or saline),
AT-RvD1 15 and 150 ng/50 μl applied spinally did not alter spinal WDR neurone firing in saline-treated rats (a-f white bars). In MIA-treated rats (a-f grey bars),
even at the higher concentration, AT-RvD1 significantly inhibited only Aδ responses (b). However, WDR neurone firings in both groups were markedly
suppressed following 1 μg/50 μl morphine (Mor) application. Data expressed as mean maximal number of action potentials post drug application. *p<
0.05, **p< 0.01, ***p< 0.0001 repeated measure ANOVA with Sidak post hoc test. #p< 0.05 Friedman test with Dunn’s post hoc test. Saline n= 7, MIA n= 9.
Note that two neurones from each group were excluded due to incomplete data sets (not receiving morphine) and identified as outliers
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strate that the model of hind paw inflammation is associated
with changes in the dorsal horn gene expression of enzymes
related to resolvin pathways. The novel inhibitory effect of
spinal AT-RvD1 was not recapitulated in a model of chronic
joint arthritis, suggesting specificity to conditions associated
with overt peripheral inflammation.The carrageenan model was associated with robust
pain behaviour, altered weight bearing and decreased
PWT, consistent with previous studies at early time-
points [20, 35]. In the present study, we extended the
period following carrageenan injection to allow the char-
acterisation of spinal events at timepoints more relevant
to injuries associated with acute inflammation and pain
Table 4 Effects of spinal AT-RvD1 versus morphine on evoked
responses of spinal neurones in MIA- and saline-treated rats
Saline-treated (n = 7) MIA-treated (n = 9)
AT-RvD1 Morphine
1 μg
AT-RvD1 Morphine
1 μg15 ng 150 ng 15 ng 150 ng
Aβ 5 ± 7 6 ± 5 28 ± 6 1 ± 8 1 ± 9 2 ± 7#
Aδ −5 ± 10 −10 ± 13 47 ± 7 11 ± 8 14 ± 10 40 ± 6
C −4 ± 7 −13 ± 9 60 ± 14 10 ± 7 3 ± 8 35 ± 8
PD −6 ± 14 −16 ± 15 70 ± 12 16 ± 24 9 ± 14 55 ± 9
Input −5 ± 15 −19 ± 21 71 ± 12 −2 ± 12 2 ± 14 58 ± 11
WU −12 ± 13 −20 ± 16 62 ± 13 17 ± 19 12 ± 12 34 ± 6
Comparison of group effects of AT-RvD1 (15, 150 ng/50 μl) and morphine
(1 μg/50 μl) on electrically evoked responses of spinal WDR neurones in MIA-
treated rats versus saline-treated rats, expressed as % maximal inhibition.
Note that negative values indicate facilitation
#p < 0.05 Mann-Whitney U test versus saline-treated rats
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the endogenous resolution pathways [36]. At the timepoint
of spinal neuronal recordings, Aδ-evoked responses of
WDR neurones significantly increased compared to the
control group. All other evoked responses of WDR neu-
rones were similar in saline- and carrageenan-treated rats.
Clearly, a limitation of quantifying the behavioural pain re-
sponse and recording the responses of WDR neurones at
this later timepoint was that baseline responses of neurones
pre-carrageenan injection could not be characterised, and
therefore, only population changes in response can be re-
ported. Previously, WDR neuronal responses characterised
before and at 3 h post carrageenan injection were reported
to exhibit increased C-fibre-evoked responses in around
half the group, and the rest had decreased response [26]. In
our study, 22 (58 %) neurons in carrageenan rats displayed
higher baseline C-fibre responses compared to the mean of
baseline C-fibre responses in non-inflamed animals, similar
to previously reported [26].
Spinal administration of AT-RvD1 attenuated C-fibre-
evoked responses of spinal neurones in carrageenan-treated
rats but not in saline controls. The magnitude of the inhibi-
tory effects of AT-RvD1 for both non-facilitated (input) and
facilitated (post-discharge) C-fibre responses of WDR neu-
rones were comparable. WU was the most sensitive to the
effects of AT-RvD1 (53 % inhibited). These data provide for
the first time a neurophysiological basis for the effects of a
resolvin molecule on spinal nociception in vivo and reveal
that these inhibitory effects are only evident under certain
conditions. Our results are in agreement with other ex vivo
spinal cord slice studies which demonstrated that RvE1 se-
lectively reduces excitatory post-synaptic potential in the
presence of the pro-inflammatory cytokine tumour necrosis
factor-α (TNF-α), by inhibiting N-methyl-D-aspartate
(NMDA) receptor activation [14], and RvD2 selectively at-
tenuates long-term potentiation of spinal neurones from in-
flamed animals [37]. To date, the reported analgesic andanti-inflammatory effects of resolvins in animal pain
models [13–15, 17] were hypothesised to be mediated by
both peripheral and central nervous system sites of action
[14]. Our demonstration of a direct spinal effect on neur-
onal responses in vivo provides a neuronal basis for the be-
havioural evidence that spinal AT-RvD1 reduces
carrageenan-induced mechanical hypersensitivity at earlier
timepoints [13]. Timecourse analysis of the effects of AT-
RvD1 revealed peak effects 30 min post administration,
with responses returning to control levels within the hour
(as shown in Additional file 1: Figure S3). Although AT-
RvD1 is more resistant to metabolism compared to RvD1
[9], the short-lived nature of action of these bioactive lipids
is a disadvantage that needs to be overcome if they are to
be harnessed as analgesics [10, 38]. The inhibitory effects of
AT-RvD1 on evoked responses of WDR neurones were
blocked by BOC-2, an antagonist for the receptor FPR2/
ALX which is thought to be coupled to Gi [11] and in
principle capable of reducing neuronal excitability. Spinal
administration of BOC-2 alone did not alter evoked neur-
onal responses in inflamed rats, suggesting limited tonic in-
hibition of spinal neuronal activity.
Spinal AT-RvD1 did not inhibit nociceptive responses
of WDR neurones in the absence of an earlier overt in-
flammatory stimulus (saline-treated) at the doses stud-
ied. Although it is possible that higher spinal doses of
AT-RvD1 may alter physiological spinal nociception in
control rats, the greater effectiveness of spinal AT-RvD1
following peripheral inflammation suggests that treat-
ments targeting this mechanism may have a window of
selectivity for inflammatory pain.
The MIA model of arthritis pain is rapidly developing
(1–2 weeks post induction) and associated with knee
joint features characteristic of human osteoarthritis and
pain behaviour [21, 22, 34, 39]. In the present study, the
effects of spinal AT-RvD1 on evoked responses of spinal
neurones were assessed at 28 days following intra-articular
injection of MIA pain, a timepoint when spinal neuronal
responses and weight bearing asymmetry are correlated
[21] and there is an increase in spinal glial fibrillary acidic
protein (GFAP) immunofluorescence, a marker of spinal
astrocyte sensitization. Reduction in PWT distal to the site
of pathology in the MIA model is considered to represent
centrally mediated receptive field expansion in osteo-
arthritis (OA) [31, 40]. Thus, delivery of the electrical
stimulation at the hind paw was used to investigate
the effect of AT-RvD1 on central sensitisation in the
MIA model. Spinal administration of AT-RvD1, at the
higher dose, produced a modest inhibition of Aδ-fibre
responses in MIA-treated rats, but all other evoked
responses of WDR neurones were unaltered. However,
our positive control spinal morphine given at the end
of the experiment clearly inhibited the evoked responses
of spinal neurones recorded in MIA rats.
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Fig. 4 Changes in gene expressions in spinal cord post intraplantar injection of saline or carrageenan. The ipsilateral dorsal horns of spinal cords
were collected at 30 h post injection; mRNA levels are relative to β-actin. mRNA levels of receptors for resolvin D and resolvin E—FPR2/ALX (a)
and ChemR23 (b), respectively, enzymes involved in resolvin biosynthesis-5-LOX (c) and 15-LOX (d), activating protein for 5-LOX—FLAP (e),
pro-inflammatory enzyme—COX-2 (f) and anti-inflammatory cytokine—IL-10 (g). Data expressed as mean ± SEM. *p < 0.05 Mann-Whitney U
test. Saline-treated n= 6, carrageenan-treated n= 5. FPR2/ALX formyl peptide receptor 2, ChemR23 chemerin receptor 23, FLAP 5-lipoxygenase-activating
protein, LOX lipoxygenase, COX-2 cyclooxygenase-2, IL-10 interleukin-10
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transmission following a period of overt peripheral inflam-
mation is suggestive of changes in the resolvin system,
compared to control conditions. Spinal expression of two
well-characterised resolvin receptors FPR2/ALX and
ChemR23 was quantified in the dorsal horn of the spinal
cord in carrageenan- and saline-treated rats. FPR2/ALX isactivated by RvD1, and AT-RvD1 and is predominantly
localised with GFAP [13, 30]. ChemR23 is expressed by
neurones [14] and localised with substance P in the central
terminals of primary afferents in the superficial dorsal
horn [14]. There was no change in FPR2/ALX receptor
mRNA level at 24 h post carrageenan injection, com-
pared to controls. There was however a significant
Meesawatsom et al. Journal of Neuroinflammation  (2016) 13:233 Page 12 of 14elevation in spinal expression of ChemR23 mRNA in
the carrageenan model of inflammatory pain compared
to controls (Fig. 4b). This observation is consistent with
the report that ChemR23 gene expression is increased
in chronic constriction model of neuropathic pain, but
not in CFA-induced paw inflammation, at days 3 and
14 post model induction [41]. Our observation that
spinal expression of ChemR23 is increased, while FPR2/
ALX was unaltered, in the carrageenan model does not
necessarily account for the increased effect of AT-RvD1
in this group of rats. Previous studies have reported
that RvD1 (structurally very similar to AT-RvD1 [9])
has negligible effect at ChemR23, whereas resolvin E1
(RvE1) has an EC50 ∼1.3 × 10
−11 M for ChemR23 [42].
On this basis, we suggest that it is unlikely that the in-
creased effectiveness of AT-RvD1 arises as a result of
an increased expression of ChemR23 in the spinal dor-
sal horn in the carrageenan model of inflammation.
In parallel with these studies, we also sought evidence
for potential changes in the spinal gene expression of
enzymes involved with resolvin biosynthesis following
the period of hind paw inflammation. We report a sig-
nificant decrease in the gene expression of 15-LOX, the
first step enzyme converting DHA to 17S-hydroperoxy
DHA (17S-H(p)-DHA) [43], in the dorsal horn of the
spinal cord in the model of carrageenan inflammation.
Expression of LOX-5, the final enzyme in the biosyn-
thesis of RvD1 and RvE1, was however unaltered in the
carrageenan model. Concomitantly, there was a signifi-
cant increase in the expression of FLAP mRNA, a key
enzyme mediating the generation of RvD1, in the dorsal
horn of the spinal cord in carrageenan-treated rats com-
pared to controls. Resolvins are endogenously generated
during the resolution phase of inflammation [7], which
is consistent with the timing of our electrophysiological
and gene expression studies. Although not proven, in-
creased expression of 15-LOX and FLAP in the dorsal
horn of the spinal cord is likely to increase baseline syn-
thesis of endogenous resolvins, which may directly
enhance the inhibitory effects of exogenous AT-RvD1, or
reduce the rate of catabolism of exogenous AT-RvD1,
leading to an increased inhibitory effect on evoked neur-
onal responses. Interrogation of this proposal is not
readily achievable as spinal blockade of LOXs and COX-
2 has analgesic effects [44, 45] or inhibits neuronal firing
[46]. Collectively, these data provide new evidence for
complex changes in key enzymes involved in the biosyn-
thesis of the resolvins in the spinal cord under specific
conditions, which require further interrogation.
Conclusions
In conclusion, spinal administration of AT-RvD1 only re-
duced peripheral nociceptive fibre-evoked responses of
spinal WDR neurones in vivo in the presence of peripheralhind paw inflammation, with minimal effects on physio-
logical spinal nociception. The ability of AT-RvD1 to select-
ively target inflammatory-driven spinal hyperexcitability of
nociceptive pathways was associated with pathway-specific
changes in the gene expression of enzymes known to medi-
ate the generation of the resolvins. Our data support the
further investigation of the analgesic potential of this class
of molecules.
Additional file
Additional file 1: Table S1. Group sizes of animals in the studies. Table
S2. Sequences of primers and probes used in the gene expression study.
Figure S1. Diagram illustrating resolvin biosynthetic pathways of resolvin
D1 (RvD1 or 17S-RvD1), AT-RvD1 (17R-RvD1) and RvE1 (18R-RvE1) and
their receptors. Genes of interest in the present study are indicated in
red. Note that AT-RvD1 in the studies was exogenously administered.
Abbreviations: ASA acetyl salicylic acid or aspirin, ChemR23 chemerin
receptor, COX-2 cyclooxygenase, CYP450 cytochrome P450, DHA
docosahexaenoic acid, FPR2/ALX formyl peptide receptor 2, 17R-H(p)-
DHA 17-R-hydroperoxy docosahexaenoic acid, 17S-H(p)-DHA 17S-
hydroperoxy docosahexaenoic acid, 15-LOX 15-lipoxygenase, 5-LOX
5-lipoxygenase. Figure S2. BOC-2 alone had no effect on spinal WDR
neurone responses in carrageenan-treated rats. Spinal administration
of BOC-2 50 μg/50 μl alone (n = 9) did not alter electrically evoked
firing of WDR neurones in carrageenan-treated rats when compared
to pre-drug responses (pre). Figure S3. Timecourse of the effects of
AT-RvD1 on electrically evoked responses of spinal WDR neurones in
carrageenan-treated rats. AT-RvD1 15 ng/50 μl was directly applied
onto the exposed spinal cord after stable baseline responses were
established. The inhibitory effects on C-fibre and post-discharge (PD)
responses peaked at 15 min post application and returned towards
control levels at 60 min. Aβ-fibre responses remained comparable to
the control level throughout the hour (n = 9 neurones). Figure S4.
An explanation of input and wind-up (WU). The graph illustrates responses in
C-fibre and post-discharge bands (90–800 post stimulus) of a WDR neurone
following a train of 16 electrical stimulations (0.5 Hz, 2-ms pulse width at 3× C-
fibre threshold). If there is no potentiation, the responses will be flat, shown as
the orange theoretical line. The input is calculated by taking the
initial response (10) multiplied by the stimulus number (16) which
results in 160. The input represents initial or non-potentiated response of
neurones. However, in the actual experiment, a WDR neurone can display
an increase in responsiveness after repetitive stimulation (shown as red line)
which is a typical characteristic. This phenomenon is called wind-up (WU)
which represents enhanced excitability. The cumulative number of action
potentials evoked by the train of stimulation (490) minus input (160) results
in calculated WU 330.
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